A Randomized, Double-Blind, Placebo Controlled Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of ABBV-0805 in Patients With Parkinson's Disease
Latest Information Update: 16 Dec 2021
At a glance
- Drugs Exidavnemab (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
Most Recent Events
- 10 Jul 2020 Status changed from recruiting to withdrawn prior to enrolment.
- 10 Jul 2020 Planned End Date changed from 24 Jul 2021 to 16 Jun 2020.
- 10 Jul 2020 Planned primary completion date changed from 24 Jul 2021 to 16 Jun 2020.